参考文献
1.Tiede B，Kang Y. From milk to malignancy：the role of mammary stem cells in development，pregnancy and breast cancer. Cell Res，2011，21：245-257.
2.Basaran G，Devrim C，Caglar HB，et al. Clinical outcome of breast cancer patients with N3a（>/=10 positive lymph nodes）disease：has it changed over years？Med Oncol，2011，28：726-732.
3.Bodmer A，Castiglione-Gertsch M. Role of hormonal manipulations in patients with hormonesensitive metastatic breast cancer. Eur J Cancer，2011，47（Suppl 3）：S28-S37.
4.Howe LR，Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res，2011，4：1149-1157.
5.LoRusso PM，Weiss D，Guardino E，et al. Trastuzumab emtansine：a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res，2011，17：6437-6447.
6.Yagata H，Kajiura Y，Yamauchi H. Current strategy for triple-negative breast cancer：appropriate combination of surgery，radiation，and chemotherapy. Breast Cancer，2011，18：165-173.
7.Lee LJ，Alexander B，Schnitt SJ，et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer，2011，117：3093-3100.
8.Perez EA，Spano JP. Current and emerging targeted therapies for metastatic breast cancer.Cancer，2012，118：3014-3025.
9.Prat A，Ellis MJ，Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol，2011，9：48-57.
10.Bueno-de-Mesquita JM，Sonke GS，van de Vijver MJ，et al. Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice.Ann Oncol，2011，22：2021-2030.
11.Jerevall PL，Ma XJ，Li H，et al. Prognostic utility of HOXB13：IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer，2011，104：1762-1769.
12.Volinia S，Galasso M，Sana ME，et al. Breast cancer signatures for invasiveness and prognosis defi ned by deep sequencing of microRNA. Proc Natl Acad Sci USA，2012，109：3024-3029.
13.Radojicic J，Zaravinos A，Vrekoussis T，et al. MicroRNA expression analysis in triple-negative（ER，PR and Her2/neu）breast cancer. Cell Cycle，2011，10：507-517.